GLP-1 drugs such as Ozempic and Wegovy may do more than help with weight loss. According to a new economic study, use of these medications was linked to a 17% decline in worker sick leave, suggesting a potential benefit for both employee health and workplace attendance.
The research points to possible financial advantages as well. If workers miss fewer days because of illness, employers could see lower absence-related costs, while employees may benefit from more consistent work time and income stability. The findings add an economic angle to the growing interest in GLP-1 medicines.
Researchers found that patients taking the drugs had fewer sick days than those not using them, based on the study highlighted by CBS News. That connection could make these medications part of a broader discussion about healthcare spending, productivity and the long-term value of obesity treatment.
Even so, the study focuses on economic outcomes tied to sick leave, not a blanket solution for every worker or employer. The results suggest GLP-1 drugs could play a role in reducing illness-related absences, while also raising new questions about access, cost and how companies evaluate health benefits.
